Older adults face a heightened risk of developing severe RSV infections. Each year the virus hospitalizes 100,000–160,000 Americans age 60 and older!
Healthy adults between 18-74 years old typically experience mild symptoms. People who are at higher risk of severe illness from RSV include:
Children with any of the following underlying conditions face an additional risk of severe RSV disease:
Because treatment options for RSV are limited, prevention is the best medicine. Below are the current preventive medication options for adults and babies:
CDC recommends RSV vaccination for all adults ages 75 and older and for adults ages 60-74 who are at increased risk of severe RSV disease (including cardiovascular disease, lung disease, neurological disease and other comorbidities. Three respiratory syncytial virus (RSV) vaccines are approved for adults ages 60 years and older:
All three vaccines are currently approved as a single dose and were shown in clinical trials to protect against symptomatic lower respiratory tract disease caused by RSV in adults ages 60 and older. Based on clinical trial data, one dose of RSV vaccine can provide protection for at least 2 years.
For pregnant women, CDC recommends a respiratory syncytial virus (RSV) vaccine protect their babies from severe RSV disease. They should get a single dose of Pfizer’s bivalent RSVpreF vaccine (during weeks 32 through 36 of pregnancy during September through January.
Children with any of the following underlying conditions face an additional risk of severe RSV disease:
Because treatment options for RSV are limited, prevention is the best medicine. Below are the current preventive medication options for adults and babies:
CDC recommends RSV vaccination for all adults ages 75 and older and for adults ages 60-74 who are at increased risk of severe RSV disease (including cardiovascular disease, lung disease, neurological disease and other comorbidities. Three respiratory syncytial virus (RSV) vaccines are approved for adults ages 60 years and older:
All three vaccines are currently approved as a single dose and were shown in clinical trials to protect against symptomatic lower respiratory tract disease caused by RSV in adults ages 60 and older. Based on clinical trial data, one dose of RSV vaccine can provide protection for at least 2 years.
For pregnant women, CDC recommends a respiratory syncytial virus (RSV) vaccine protect their babies from severe RSV disease. They should get a single dose of Pfizer’s bivalent RSVpreF vaccine (during weeks 32 through 36 of pregnancy during September through January.
Children with any of the following underlying conditions face an additional risk of severe RSV disease:
Because treatment options for RSV are limited, prevention is the best medicine. Below are the current preventive medication options for adults and babies:
CDC recommends RSV vaccination for all adults ages 75 and older and for adults ages 60-74 who are at increased risk of severe RSV disease (including cardiovascular disease, lung disease, neurological disease and other comorbidities. Three respiratory syncytial virus (RSV) vaccines are approved for adults ages 60 years and older:
All three vaccines are currently approved as a single dose and were shown in clinical trials to protect against symptomatic lower respiratory tract disease caused by RSV in adults ages 60 and older. Based on clinical trial data, one dose of RSV vaccine can provide protection for at least 2 years.
For pregnant women, CDC recommends a respiratory syncytial virus (RSV) vaccine protect their babies from severe RSV disease. They should get a single dose of Pfizer’s bivalent RSVpreF vaccine (during weeks 32 through 36 of pregnancy during September through January.
In cases where RSV makes its way down into the lungs, causing lower respiratory tract disease (LRTD), it can cause higher-risk individuals to experience life-threatening complications such as pneumonia. LRTD can also worsen some existing conditions such as asthma, congestive heart failure, and chronic obstructive pulmonary disease (COPD), worse. Each year, this leads to 6,000-10,000 deaths.
All infants are at risk of developing a severe RSV infection.
Children with any of the following underlying conditions face an additional risk of severe RSV disease:
Because treatment options for RSV are limited, prevention is the best medicine. Below are the current preventive medication options for adults and babies:
CDC recommends RSV vaccination for all adults ages 75 and older and for adults ages 60-74 who are at increased risk of severe RSV disease (including cardiovascular disease, lung disease, neurological disease and other comorbidities. Three respiratory syncytial virus (RSV) vaccines are approved for adults ages 60 years and older:
All three vaccines are currently approved as a single dose and were shown in clinical trials to protect against symptomatic lower respiratory tract disease caused by RSV in adults ages 60 and older. Based on clinical trial data, one dose of RSV vaccine can provide protection for at least 2 years.
For pregnant women, CDC recommends a respiratory syncytial virus (RSV) vaccine protect their babies from severe RSV disease. They should get a single dose of Pfizer’s bivalent RSVpreF vaccine (during weeks 32 through 36 of pregnancy during September through January.
To learn more regarding any safety concerns, see ACIP Contraindications Guidelines for Immunization,
For Immunization Best Practices Guidelines for health professionals, see RSV (Respiratory Syncytial Virus) Immunizations | CDC
Phone: 856-866-7466